Profiling a relapse AML cohort and leveraging in vivo functional genomics, we uncovered an actionable SRRM1–CLK1/4–PAK1 node driving chemoresistance and MAP2K5 missplicing as a key relapse-associated event. Dual PAK1/CLK1/4 inhibition restores chemosensitivity.
